Turning Point Brands (TPB) Q3 2026 earnings review
Turning Point Brands doubles pouch sales, but profit drops 41%
Turning Point Brands, the maker of Zig-Zag rolling papers and Stoker's tobacco, now gets nearly half its revenue from FRE and ALP nicotine pouches, but marketing them still cuts profit in half. Total net sales rose 27% to $151 million as pouch revenue doubled, while EBITDA excluding one-offs fell 41% to $18 million. New chief executive David Glazek kept the full-year outlook from September, which by our math leaves fourth-quarter pouch sales slightly below the third quarter at the middle of the range.
| Net sales | $151.1M +27.0% from a year ago |
|---|---|
| Modern Oral pouch net sales | $74.4M +102.9% from a year ago (49.2% of total sales) |
| EBITDA, excluding one-offs | $18.4M -41.3% from a year ago |
| Full-year EBITDA outlook, excluding one-offs | $70–80M top end trimmed $10M from Q2's $70–90M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because rapid pouch growth and heavy upfront spending are both running along the path set last quarter. Store discounts did not widen during the autumn retail resets, and the company bought back $10 million of stock after issuing shares earlier in the year. One caution: the company trimmed $10 million off the top of its full-year EBITDA range in September, and nine-month FDA application costs have already passed the $3–5 million annual budget.
The question now is when doubling pouch sales begins to lift profit instead of draining it. Either store reorders and the new Louisville factory start returning cash in 2027, or promotion against giant tobacco rivals eats up every new dollar of sales. The initial 2027 profit and spending outlook next quarter will settle it.
🐂 Bull Case
Nicotine Pouches Now Drive Half of Revenue
Turning Point Brands is remaking itself around Modern Oral, its business selling FRE and ALP nicotine pouches. New chief executive David Glazek said marketing and store-placement spending on the two brands is "positioning us to become a leading player in the rapidly growing nicotine pouch category."
The pouch unit doubled its net sales from a year ago to $74.4 million and added $6.0 million from the second quarter. It now brings in 49.2% of total company revenue, up from 30.8% a year ago, lifting total Stoker's segment sales 52.0% to $113.8 million.
That growth kept the company moving forward while its older smoking accessories shrank, and by our math traditional Stoker's moist snuff and loose-leaf chewing tobacco grew 3.3% to $39.4 million. However, keeping the full-year pouch outlook at $260–270 million leaves $65.2–75.2 million for the fourth quarter by our math, pointing to a slight sequential drop at the middle of the range.
What to watch: fourth-quarter Modern Oral net sales and the initial 2027 pouch outlook on the next call. A fourth-quarter result above $74.4 million would show the unchanged annual forecast was cautious rather than a sign that retail demand is stalling.
Store Discounts Did Not Widen in Q3
As Turning Point pushes its FRE and ALP nicotine pouches into convenience store chains, it pays slotting fees and promotional discounts that sit between gross billings and reported net sales. In the third quarter, gross pouch sales rose 114.2% to $93.9 million while net sales reached $74.4 million.
By our math, the tobacco group kept 79.2% of its gross pouch sales as net revenue, up from 78.6% in the second quarter and 75.4% in the first. Holding that spread near 79% during the autumn chain-store reset season matters because it shows the company is adding shelf space without giving away a larger cut of each can sold.
What to watch: the ratio of net to gross Modern Oral sales in the fourth quarter. By our math, the middle of the full-year outlook implies a 77.9% ratio for the final quarter, so a reading near 79% would show promotional pressure remains contained.
🐻 Bear Case
Pouch Growth Still Cuts Profit in Half
Selling twice as many nicotine pouches is still shrinking the bottom line because pouches carry lower gross margins than traditional tobacco and require heavy upfront marketing. Turning Point trimmed the top end of its full-year EBITDA outlook, excluding one-offs, by $10 million in an update "updated on September 21, 2026", leaving the range at $70–80 million.
- Selling, general and administrative expenses: $75.3 million, up 12.4 percentage points of net sales from a year ago to 49.8%
- Stoker's segment gross margin: 56.0%, down 4.2 percentage points "primarily driven by a shift in product mix toward Modern Oral"
- Operating margin: 6.5% of net sales, down 15.2 percentage points from 21.8% a year ago
- EBITDA, excluding one-offs: $18.4 million, down 41.3% from a year ago but up 20.7% from the second quarter
Because the company is spending every extra dollar of gross profit on sales staff, marketing and outbound freight, revenue growth has not yet turned into earnings growth. By our math, the trimmed annual target leaves $10.5–20.5 million of fourth-quarter EBITDA, excluding one-offs, down 48.5% from a year ago at the middle of the range.
What to watch: selling, general and administrative expenses as a share of net sales in the fourth quarter and the 2027 EBITDA outlook. Until overhead and marketing drop well below half of revenue, rapid pouch growth will not restore prior profit levels.
Zig-Zag Sales Still Fall From Last Year
Chief executive David Glazek pointed to "progress across our heritage brands" alongside the pouch boom. Zig-Zag, the company's rolling papers and cigar-wraps business that makes up a quarter of total revenue, did edge up 5.5% from the second quarter to $37.3 million.
Against a year ago, however, Zig-Zag net sales fell 15.5% and segment gross profit dropped 15.6% to $21.4 million, marking a sixth straight quarter of year-over-year contraction. Part of the drop reflects winding down the Clipper lighter distribution partnership, which management previously called an accepted cost of shifting sales staff to nicotine pouches. Because Zig-Zag carries a 57.4% gross margin and needs little extra marketing, its decline removes high-margin dollars that used to fund the rest of the business.
What to watch: Zig-Zag fourth-quarter net sales against last year's $40.0 million, when the Clipper wind-down was already underway. A seventh straight year-over-year decline would show the rolling-papers business is still losing ground beyond the discontinued lighter line.
FDA Application Costs Keep Rising Without Approval
To keep FRE and ALP on the US market long term and open its Louisville, Kentucky pouch factory, Turning Point needs premarket tobacco product application (PMTA) approvals from the Food and Drug Administration. The third-quarter release gave no update on when the regulator might rule or when domestic production will begin.
Meanwhile, the cost of pursuing those approvals keeps climbing: the company spent $3.15 million on FDA applications in the quarter, up from $0.48 million a year ago, and logged another $0.59 million in factory start-up costs. By our math, nine-month FDA application spending has reached $6.61 million, already above the $3–5 million full-year modeling assumption management set earlier this year.
What to watch: commentary in the quarterly filing or on the call regarding Louisville line qualification before year-end. Until domestic lines run commercially, pouch gross margins remain exposed to overseas sourcing and freight costs.
Risks this quarter didn't answer
Three standing concerns about pouch ownership, competition and share issuance were not resolved in the earnings release.
- Joint-venture profit split: Turning Point owns 50% of ALP and paid $2.92 million of third-quarter net income to its non-controlling partner (42.6% of consolidated net income, against $3.93 million kept by Turning Point), while still withholding the FRE versus ALP revenue split.
- Incumbent promotional pressure: larger tobacco rivals are running heavy price promotions in pouches; the release gives no standalone gross margin for Modern Oral to show whether unit pricing is holding.
- Remaining share-issuance capacity: diluted shares are still up 8.4% from a year ago at 20.28 million after two equity raises in the past four quarters, and management has not stated what governs the remaining at-the-market equity program.
👓 Other Themes
David Glazek Takes Over as Chief Executive
David Glazek signed the third-quarter release as chief executive officer, succeeding Graham Purdy and noting, "I have been involved with Turning Point Brands for nearly 14 years and have never been more optimistic about its future." Alongside the leadership change, the company bought back 167,161 shares for $10.0 million at an average price of $59.82, just one quarter after issuing $59.5 million of new stock at $90.30 per share.
💲 Other KPIs
Inventories rose 23.6% from a year ago and are up $31.4 million since December 2025 as the tobacco group stocks FRE and ALP pouches for retail chain rollouts. The buildup has climbed for four straight quarters, tying up working capital ahead of the holiday and autumn store-reset seasons.
Cash from operations over the first nine months fell 70.9% from $32.5 million a year ago because the $31.6 million inventory buildup absorbed most of the period's profit. By our math, third-quarter operating cash flow turned positive at $5.4 million, lifting quarterly free cash flow to $3.5 million after a negative first half.
Net debt — total borrowings minus unrestricted cash — rose from $31.7 million at the end of June after the US consumer group spent $10.0 million on share buybacks and $7.0 million on an option agreement, reducing unrestricted cash to $251.3 million. It remains down by half from $98.8 million a year ago.
🔮 Guidance
Unchanged. The full-year target for gross pouch billings stays at $330–350 million after two raises earlier in the year. With $249.9 million recorded across the first nine months by our math, the plan leaves $80.1–100.1 million for the fourth quarter, or $90.1 million at the middle of the range — 4.0% below the third quarter's $93.9 million.
Unchanged. Management kept the net pouch revenue plan at $260–270 million, about double last year's $130.4 million. By our math, nine-month net sales of $194.8 million leave $65.2–75.2 million for the fourth quarter (70.0% growth from a year ago at the middle of the range, but down 5.6% from the third quarter). It is the first quarter this year without a raise after hikes of $32.5 million in Q1 and $47.5 million in Q2.
Cut. The release reaffirmed the $70–80 million range set on September 21, which trimmed $10 million off the top of the $70–90 million outlook carried in the second-quarter report. At the $75.0 million middle of the range, full-year EBITDA excluding one-offs falls 37.3% from last year's $119.5 million. By our math, that leaves $10.5–20.5 million for the fourth quarter, down 48.5% from a year ago at the middle.
❓ Key Questions
Why does the outlook imply lower Q4 pouch sales?
By our math, the $260–270 million Modern Oral net sales outlook leaves $70.2 million at the middle of the range for the fourth quarter, below Q3's $74.4 million. Is management planning for seasonal slowdowns, higher chain slotting fees, or simple caution?
What is the status of the Louisville pouch factory?
Management previously aimed to launch US pouch manufacturing by year-end subject to regulatory approval, and spent another $593,000 on start-up costs in Q3. Have the domestic lines qualified, and does commercial launch still wait on FDA action?
Why have FDA application costs topped the full-year budget?
FDA premarket application expenses hit $3.15 million in Q3 and $6.61 million over nine months, above the $3–5 million full-year modeling assumption from earlier this year. What drove the extra spending, and when will it end?
What is the revenue split between FRE and ALP?
Non-controlling interest took $2.92 million of Q3 net income (42.6% of the consolidated total) through the 50%-owned ALP joint venture, yet management still withholds how much of the $74.4 million in pouch sales comes from ALP versus wholly owned FRE.
What rules govern share issuance versus buybacks?
Turning Point issued $59.5 million of stock at $90.30 per share in the second quarter, then spent $10.0 million buying back shares at $59.82 in the third. Will management retire the remaining at-the-market equity issuance program?